Treatment of neuroblastoma with metaiodobenzylguanidine: Results and side effects

✍ Scribed by Treuner, Jörn ;Klingebiel, Thomas ;Bruchelt, Gernot ;Feine, Ullrich ;Niethammer, Dietrich

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 337 KB
• Volume: 15
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950150412

✦ Synopsis

Between April 1984 and December 1985 we treated ten children suffering from neuroblastoma in a total of 25 metaiodobenzylguanidine (MIBG) courses. Five had had a relapse of neuroblastoma stage III or IV, three had never achieved a remission in spite of intensive chemotherapy, and two were treated with an unstable remission. The children were each administered from 1 to 5 courses with a dosage per course of between 1,295 and 9,065 MBq. The sum of the single doses during the whole course of therapy ranged between 3,145 and 21,904 MBq per child. Five of five children suffering from bone pain and fever became free of complaints during the first three treatment days. Six of eight children with manifest tumor at onset of therapy responded well to the treatment: response extended from transitory decrease in elevated catecholamine levels in serum and urine to complete disappearance of large abdominal tumor masses. We also observed a decrease in bone marrow involvement and a stabilization of osteolytic lesions. Seven of these eight children died in spite of a good response from 55 to 350 days after the first MIBG treatment course. The only side effect we witnessed was a reversible bone marrow depression. In three children we combined the MIBG therapy with bone marrow transplantation.